Evidence map›Paper›PMID 41673649›Full record

ArticleCell communication and signaling : CCS2026

Bone morphogenetic protein receptor 2 signaling mediates mitochondrial Ca

Ashley Toussaint, Manohar Singh, Hellen Chiou, Guoqiang Wang, Dongxuan Jia, Monica Driscoll, Vrushank Bhatt, Jean De La Croix Ndong, Sahil Shuaib, Harrison Zoltowski and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ashley Toussaint *Department of Surgery, Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, NJ, New Brunswick, 08903, USA.
Manohar Singh *Department of Surgery, Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, NJ, New Brunswick, 08903, USA.
Hellen ChiouDepartment of Surgery, Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, NJ, New Brunswick, 08903, USA.
Guoqiang WangRutgers Robert Wood Johnson Medical School, Molecular Biology and Biochemistry at Rutgers, New Brunswick, USA.
Dongxuan JiaDepartment of Surgery, Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, NJ, New Brunswick, 08903, USA.
Monica DriscollRutgers Robert Wood Johnson Medical School, Molecular Biology and Biochemistry at Rutgers, New Brunswick, USA.
Vrushank BhattRutgers Cancer Institute of NJ, New Brunswick, USA.
Jean De La Croix NdongDepartment of Surgery, Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, NJ, New Brunswick, 08903, USA.
Sahil ShuaibRutgers State University of New Jersey, New Brunswick, USA.
Harrison ZoltowskiRutgers State University of New Jersey, New Brunswick, USA.
John GilleranMolecular Design and Synthesis at Rutgers, New Brunswick, USA.
Youyi PengRutgers Cancer Institute of NJ, New Brunswick, USA.
Anastasiia TsymbalMolecular Design and Synthesis at Rutgers, New Brunswick, USA.
Jacques RobergeMolecular Design and Synthesis at Rutgers, New Brunswick, USA.
Jessie Yanxiang GuoRutgers Cancer Institute of NJ, New Brunswick, USA.
Daniel HerranzRutgers Cancer Institute of NJ, New Brunswick, USA.
John LangenfeldDepartment of Surgery, Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, NJ, New Brunswick, 08903, USA. langenje@cinj.rutgers.edu.

Funding

Targeting BMP type 2 receptor for the treatment of breast cancer.R01CA225830 · NCI · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI LANGENFELD, JOHN · 2018 to 2022
$3.2M
NIH HHS R01 CA225830
6 · The paper itself

Abstract

backgroundBone morphogenetic proteins (BMPs) are highly conserved multifunctional signaling proteins with pleotropic effects throughout embryonic development. BMPs are aberrantly expressed in many diseases including cancer and Alzheimer's disease. Recent studies suggested that BMP signaling negatively regulates mitochondrial bioenergetics. The mechanisms by which BMP signaling regulates bioenergetics and cell survival are not known.

methodsWe utilized BMP type 2 receptor (BMPR2) inhibitor (JL189), BMPR2 kinase domain KO, BMPR2 siRNA, and BMP loss of function mutants in C. elegans to inhibit BMP signaling (BMPR2i). The effects of BMPR2i on mitochondrial bioenergetics were examined by measuring differences in TCA cycle intermediates (mass spectrometer), mitochondrial respiration (Agilent Seahorse), and mitochondrial mass (MitoTracker Green/TFAM). Fluorescent mitochondrial Ca

resultsBMPR2i increased mitochondrial Ca

conclusionThese studies reveal that BMPR2 signaling regulates TAK1-d splice variant to mediate mitochondrial Ca

Indexed as

Alternative SplicingBone Morphogenetic Protein Receptors, Type IICalciumMAP Kinase Kinase KinasesMitochondriaSignal TransductionAnimalsCaenorhabditis elegansHumansMAP Kinase Kinase Kinase 7Protein IsoformsBone Morphogenetic Protein Receptors, Type IICalciumMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesProtein IsoformsBMP inhibitorCell deathMCUMitochondrial calciumTAK1

Identifiers

PMID41673649
PMCPMC12998070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.